We are live on ! Find out more
MBX

MBX Biosciences
MBX

79 hedge funds and large institutions have $263M invested in MBX Biosciences in 2025 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 24 increasing their positions, 15 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

160% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 10

60% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 15

25% more funds holding

Funds holding: 63 → 79 (+16)

8.15% more ownership

Funds ownership: 98.57% → 106.72% (+8.2%)

57% less capital invested

Capital invested by funds: $606M → $263M (-$343M)

67% less funds holding in top 10

Funds holding in top 10: 3 → 1 (-2)

Holders
79
Holders Change
+16
Holders Change %
+25.4%
% of All Funds
1.06%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.01%
New
26
Increased
24
Reduced
15
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
MB
MPM BioImpact
Massachusetts
+$12M
2
WP
Woodline Partners
California
+$2.84M
3
OM
Opaleye Management
Massachusetts
+$2.64M
4
JP Morgan Chase
JP Morgan Chase
New York
+$2.03M
5
O
OrbiMed
New York
+$2.02M

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$4.06M
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$3.22M
3
Wellington Management Group
Wellington Management Group
Massachusetts
-$2.87M
4
Millennium Management
Millennium Management
New York
-$1.73M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$641K
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
76
Sterling Capital Management
North Carolina
$672 -$740 -70 -43%
GI
77
GAMMA Investing
California
$148 +$211 +20 New
EWA
78
EverSource Wealth Advisors
Alabama
$66 +$95 +9 New
TWD
79
True Wealth Design
Ohio
$23 +$32 +3 New
Citadel Advisors
80
Citadel Advisors
Florida
– -$4.06M -220,330 Closed
Alyeska Investment Group
81
Alyeska Investment Group
Illinois
– -$3.22M -174,700 Closed
TRSOTSOK
82
Teachers Retirement System of the State of Kentucky
Kentucky
– -$492K -26,708 Closed
Norges Bank
83
Norges Bank
Norway
– -$461K -25,000 Closed
SVCM
84
Saturn V Capital Management
Texas
– -$332K -18,000 Closed
BC
85
BIT Capital
Germany
– -$235K -12,743 Closed
MIM
86
MetLife Investment Management
New Jersey
– -$133K -7,230 Closed
SIM
87
Sandia Investment Management
Massachusetts
– -$92.2K -5,000 Closed
VEA
88
Virtus ETF Advisers
New York
– -$63.9K -3,468 Closed
RS
89
R Squared
Hong Kong
– -$7.37K -400 Closed
1 2 3
4

MBX Hedge Fund Activity: Q1 2025 in Review

79 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in MBX Biosciences (MBX) for Q1 2025, worth a combined $263M — down 57% from $606M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new MBX positions and 10 closed out — a net gain of 16 holders — while 24 added to existing stakes and 15 trimmed.

The largest buyer was MPM BioImpact, opening a new position worth an estimated $12M. The largest seller was Citadel Advisors, exiting entirely with an estimated $4.06M sold.

  • 79 institutional investors held MBX Biosciences (MBX) as of Q1 2025, up from 63 in Q4 2024.
  • Funds reported $263M of MBX Biosciences stock for Q1 2025, down 57% quarter-over-quarter.
  • 26 funds opened new MBX Biosciences positions in Q1 2025 and 10 closed out, a net change of +16 holders.
  • The largest MBX Biosciences buyer in Q1 2025 was MPM BioImpact, an estimated $12M added.
  • The largest MBX Biosciences seller in Q1 2025 was Citadel Advisors, an estimated $4.06M sold.

Based on aggregated 13F filings for Q1 2025.